Lakefront Biotherapeutics N.V. logo

Lakefront Biotherapeutics N.V.

LKFT | NASDAQ
Chart Builder DCF Calculator
$32.28
-$0.05 (-0.15%)
At close: Oct 30, 2026, 4:00 PM ET
$32.52
+$0.24 (+0.74%)
Pre-market: Nov 2, 2026, 7:10 AM ET

Market Data

Market Cap
$2.11B
Enterprise Value
$-381.55M
Beta
0.12
Average Volume
249.79K
Shares Outstanding (Diluted)
66.93M
Shares Change YoY
1.56%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US36315X1019

Price Performance

Price Change 1M
8.9%
Price Change 3M
18.6%
Price Change 6M
15.3%
Price Change YTD
-1.3%
Price Change 1Y
1.6%
Price Change 3Y
-3.5%
Price Change 5Y
-39.1%
1M CAGR (ann.)
13.1%
1Y CAGR (ann.)
4.4%
5Y CAGR (ann.)
-8.7%
All-Time CAGR
-5.8%

Valuation

PE Ratio
3.06
Forward PE
N/A
PEG Ratio
-0.10
Forward PEG
-0.07
PS Ratio
1.83
Forward PS
47.70
PB Ratio
0.57
P/FCF Ratio
-9.18
P/Adj. FCF Ratio
-9.18
P/OCF Ratio
-6.23
EV/Sales
-0.39
EV/EBIT
-0.72
EV/EBITDA
-0.70
EV/FCF
1.93
Earnings Yield
31.5%
FCF Yield
-10.5%
Adj. FCF Yield
-10.5%

Financial Health

Net Cash
€2.24B
Total Debt
€6.36M
Cash & Short-Term Investments
€2.24B
Total Assets
€3.35B
Current Ratio
30.48
Quick Ratio
30.30
Debt / Equity Ratio
0.00
Debt / EBITDA
0.01
Debt / FCF
-0.03
OCF / Debt
-30.32
Interest Coverage
171.26
Altman Z-Score
14.67
Piotroski F-Score
5

Margins & Profitability

Gross Profit Margin
98.0%
Operating Profit Margin
61.6%
EBITDA Margin
33.3%
Net Profit Margin
46.8%
FCF Margin
-19.9%
Adj. FCF Margin
-19.9%
SBC / Revenue
-1.2%
SBC Impact (per share)
N/A

Returns

Return on Assets
14.5%
Return on Equity
16.9%
Return on Invested Capital
11.6%
Return on Capital Employed
11.6%
Return on Tangible Assets
14.5%

Historical Growth (CAGR)

Revenue CAGR 3Y
42.1%
Revenue CAGR 5Y
N/A
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
296.4%
EPS CAGR 5Y
N/A
EPS CAGR 10Y
N/A
FCF CAGR 3Y
N/A
FCF CAGR 5Y
N/A
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
2
EPS Growth Next 3Y
-44.6%
Revenue Growth Next 3Y
-66.4%
Earnings Date
Nov 11, 2026
EPS Estimate (next Q)
-$0.93
EPS Growth Est (next Q)
-76.5%
Revenue Est (next Q)
$8.43M
Revenue Growth Est (next Q)
-90.9%

Fair Value Estimates

Graham Number
$114.52
Graham Upside
254.8%
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$35.50
Price Target Upside
10.0%

Cash Flow

Operating Cash Flow
€-192.82M
Free Cash Flow
€-197.4M
Adj. Free Cash Flow
€-197.4M
FCF Per Share
-$4.57
OCF Per Share
-$4.44
OCF/S Ratio
-28.0%

Income Statement

Revenue
€990.58M
Gross Profit
€939.84M
Operating Income
€609.93M
EBITDA
€541.6M
Net Income
€596.64M
EPS (Diluted)
$9.05
Revenue / Employee
$2.19M
Profit / Employee
$1.32M
Employees
452

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.